Gabriele Simonini
Gabriele Simonini is an expert in Rheumatology at Meyer Children's Hospital (Italy) (Italy). As of October 2026, ScienceLeadR ranks Gabriele Simonini in the top 1% of experts worldwide for Uveitis, Uveal Diseases and Vasculitis. Gabriele Simonini has authored 391 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 12 of them ongoing. SLR score: 1,381 (community average: 125). How the SLR is computed.
LeadR Profile
Rheumatology
Subspecialties: Pediatrics - Immunology - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 391
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Validity of the 2023 ACR/EULAR APS classification criteria to pediatric primary APS: inputs from a systematic literature review. PMID 42902782 — laboratories, classification, rheumatic diseases | Rheumatology (Oxford) | 2026 | 0 |
| Early Introduction and Prolonged Full-Dose Anakinra Reduce Recurrence Risk After Discontinuation in Recurrent Pericarditis: An International Multicenter Cohort. PMID 42885757 — heart diseases, pharmaceutical preparations, duration of therapy, pericarditis, maintenance, therapeutics | J Am Heart Assoc | 2026 | 0 |
| Treatment and Outcomes of Kawasaki Disease Over 40 Years. PMID 42722374 — pericardial effusion, aneurysm, mucocutaneous lymph node syndrome, therapeutics, child, immunoglobulins, intravenous | Pediatrics | 2026 | 2 |
| Genetic variation in SLCO1B1 is associated with methotrexate intolerance symptoms in juvenile idiopathic arthritis patients. PMID 42690100 — genetic variation, pharmacogenetics, incidence, arthritis, signs and symptoms, alleles, precision medicine, folic acid, arthritis, juvenile, methotrexate | Pharmacogenet Genomics | 2026 | 0 |
| Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis. PMID 42642883 — research design, osteomyelitis, pain, arthritis, patient reported outcome measures, information systems, child | Arthritis Care Res (Hoboken) | 2026 | 0 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
12 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Safety tolerability pharmacokinetics and efficacy of filgotinib for the treatment of polyarticular course juvenile idiopathic arthritis in children and adolescents 2024-511593-70-00 — safety, arthritis, adolescent, therapeutics, arthritis, juvenile, child, pharmacokinetics | Phase 3 | Recruiting | 2026 |
| Study of Oral Upadacitinib and Subcutaneous Intravenous Tocilizumab to Evaluate Change in Disease Activity Adverse Events and how Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis 2022-501599-25-00 — safety, pharmaceutical preparations, arthritis, drug-related side effects and adverse reactions, adolescent, arthritis, juvenile, pharmacokinetics | Phase 3 | Recruiting | 2024 |
| Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial NCT07699107 — injections, tumor necrosis factor-alpha, uveitis, anterior, pharmaceutical preparations, syringes, neoplasms, arthritis, uveitis, intermediate, solutions, necrosis, adalimumab, therapeutics, arthritis, juvenile, injections, subcutaneous, uveitis, biosimilar pharmaceuticals | Phase 4 | Not yet recruiting | 2026 |
| A Phase 3 Study to Evaluate the Pharmacokinetics Efficacy and Safety of Deucravacitinib (BMS 986165) in Pediatric Participants with Juvenile Psoriatic Arthritis 2024-517262-41-00 — arthritis, psoriatic, safety, arthritis, adolescent, child, pharmacokinetics | Phase 3 | Recruiting | 2025 |
| An open label phase II trial to evaluate the clinical efficacy safety and tolerability of MAS825 in pediatric and adult participants with Still s disease 2024-520208-25-00 — safety | Phase 2 | Recruiting | 2026 |
LeadR Networks
Main global connection map